Your browser doesn't support javascript.
Clinical Characteristics, Care Trajectories and Mortality Rate of SARS-CoV-2 Infected Cancer Patients: A Multicenter Cohort Study.
Benderra, Marc-Antoine; Aparicio, Ainhoa; Leblanc, Judith; Wassermann, Demian; Kempf, Emmanuelle; Galula, Gilles; Bernaux, Mélodie; Canellas, Anthony; Moreau, Thomas; Bellamine, Ali; Spano, Jean-Philippe; Daniel, Christel; Champ, Julien; Canouï-Poitrine, Florence; Gligorov, Joseph.
  • Benderra MA; Medical Oncology Department, AP-HP Greater Paris University Hospital, Tenon Hospital, 75020 Paris, France.
  • Aparicio A; Institut Universitaire de Cancérologie AP-HP Sorbonne Université, Sorbonne Université, 75006 Paris, France.
  • Leblanc J; Alliance Pour la Recherche en Cancérologie, 75020 Paris, France.
  • Wassermann D; Clinical Research Platform of East of Paris, AP-HP greater Paris University Hospital, Sorbonne Université Hospitals, 75020 Paris, France.
  • Kempf E; Clinical Research Platform of East of Paris, AP-HP greater Paris University Hospital, Sorbonne Université Hospitals, 75020 Paris, France.
  • Galula G; Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP), 75011 Paris, France.
  • Bernaux M; Institut National de Recherche en Informatique et en Automatique, INRIA Saclay Île-de-France, 78150 Palaiseau, France.
  • Canellas A; Medical Oncology Department, AP-HP Greater Paris University Hospital, Henri-Mondor Hospital, 94000 Creteil, France.
  • Moreau T; Medical Oncology Department, AP-HP Greater Paris University Hospital, Tenon Hospital, 75020 Paris, France.
  • Bellamine A; Cancer Group, AP-HP Greater Paris University Hospital, 75004 Paris, France.
  • Spano JP; AP-HP Greater Paris University Hospital, DST, 75012 Paris, France.
  • Daniel C; Institut Universitaire de Cancérologie AP-HP Sorbonne Université, Sorbonne Université, 75006 Paris, France.
  • Champ J; Pneumology Department, AP-HP Greater Paris University Hospital, Tenon Hospital, 75020 Paris, France.
  • Canouï-Poitrine F; Université Paris-Saclay, Inria, CEA, 91120 Palaiseau, France.
  • Gligorov J; AP-HP Greater Paris University Hospital, DSI-WIND, 75006 Paris, France.
  • On Behalf Of The Ap-Hp/Universities/Inserm Covid-Research Collaboration; Institut Universitaire de Cancérologie AP-HP Sorbonne Université, Sorbonne Université, 75006 Paris, France.
  • Cancer Ap-Hp Group Covid-Task Force; Medical Oncology Department, AP-HP Greater Paris University Hospital, Pitie-Salpetriere Hospital, Paris 75013, France.
  • Ap-Hp Covid Cdw Initiative Acci; Institut Pierre Louis d'Épidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (Inserm) 1136, Sorbonne Université, Paris 75013, France.
Cancers (Basel) ; 13(19)2021 Sep 23.
Article in English | MEDLINE | ID: covidwho-1438522
ABSTRACT

BACKGROUND:

COVID-19 may be more frequent and more severe in cancer patients than in other individuals. Our aims were to assess the rate of COVID-19 in hospitalized cancer patients, to describe their demographic characteristics, clinical features and care trajectories, and to assess the mortality rate.

METHODS:

This multicenter cohort study was based on the Electronic Health Records of the Assistance Publique-Hôpitaux de Paris (AP-HP). Cancer patients with a diagnosis of COVID-19 between 3 March and 19 May 2020 were included. Main outcome was all-cause mortality within 30 days of COVID-19 diagnosis.

RESULTS:

A total of 29,141 cancer patients were identified and 7791 (27%) were tested for SARS-CoV-2. Of these, 1359 (17%) were COVID-19-positive and 1148 (84%) were hospitalized; 217 (19%) were admitted to an intensive care unit. The mortality rate was 33% (383 deaths). In multivariate analysis, mortality-related factors were male sex (aHR = 1.39 [95% CI 1.07-1.81]), advanced age (78-86 y aHR = 2.83 [95% CI 1.78-4.51] vs. <66 y; 86-103 y aHR = 2.61 [95% CI 1.56-4.35] vs. <66 y), more than two comorbidities (aHR = 2.32 [95% CI 1.41-3.83]) and C-reactive protein >20 ng/mL (aHR = 2.20 [95% CI 1.70-2.86]). Primary brains tumors (aHR = 2.19 [95% CI 1.08-4.44]) and lung cancer (aHR = 1.66 [95% CI 1.02-2.70]) were associated with higher mortality. Risk of dying was lower among patients with metabolic comorbidities (aHR = 0.65 [95% CI 0.50-0.84]).

CONCLUSIONS:

In a hospital-based setting, cancer patients with COVID-19 had a high mortality rate. This mortality was mainly driven by age, sex, number of comorbidities and presence of inflammation. This is the first cohort of cancer patients in which metabolic comorbidities were associated with a better outcome.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Observational study / Prognostic study Language: English Year: 2021 Document Type: Article Affiliation country: Cancers13194749

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Observational study / Prognostic study Language: English Year: 2021 Document Type: Article Affiliation country: Cancers13194749